ChemBriefElectra Therapeutics Targets $977.6 Million Valuation in US IPO
Electra Therapeutics targets a $977.6 million valuation in its U.S. IPO to fund clinical trials for its lead drug ipsoprubart and candidate ELA822 targeting immunological diseases and cancer. The comp
reuters · 2026-09-14 03:59